Eightcap
Dukascopy
VS
Higher Rated
Dukascopy
Capital at risk · T&Cs apply
Compare Eightcap and Dukascopy side by side on fees, regulation, platforms and our expert ratings. Find out which broker suits your needs.
Eightcap
Dukascopy
Dukascopy is the better choice overall, scoring 3.7/5 vs 3.6/5 on BrokerRank's independent rating. On fees, Eightcap offers lower spreads (0 pips).
See full side-by-side comparison belowOverall Rating
Dukascopy
3.6 vs 3.7
Lowest Fees
Eightcap
0 vs 0.1 pips
Regulation
Eightcap
3 vs 2 licences
Min. Deposit
Tied
$100 vs $100
Eightcap
WinnerDukascopy
Eightcap
Lower feesDukascopy
Eightcap scores 3.62/5 while Dukascopy scores 3.71/5 in our independent rating.
Dukascopy edges ahead overall, but Eightcap may suit traders who prioritise different features. Read our full reviews for a detailed breakdown. Scores are based on our transparent methodology.
Dukascopy scores higher overall on our independent rating system. Eightcap holds a 3.6/5 rating vs Dukascopy's 3.7/5. The best choice ultimately depends on your trading style — see our full verdict above for a detailed breakdown.
Eightcap offers spreads from 0 pips, while Dukascopy starts at 0.1 pips. Check the fees section above for a full breakdown.
Eightcap requires a minimum deposit of $100. Dukascopy requires $100.
Eightcap is regulated by ASIC, FCA, CySEC, while Dukascopy holds licences from FCA, MAS.
Eightcap supports MT4, MT5. Dukascopy supports Proprietary Web, Proprietary Mobile, MT4.
Yes, you can hold accounts at multiple brokers simultaneously. Many traders diversify across platforms to access different markets and tools.
Only 26% of Brokers Are Truly Fee-Free
BrokerRank Research — Hidden costs across 345 brokers
58% of Brokers Hold a Single Licence
BrokerRank Research — Regulation quality analysis
71% of Retail Traders Lose Money
BrokerRank Research — Loss rates across 50 EU brokers
76% of Brokers Use Proprietary Platforms
BrokerRank Research — MT4 vs MT5 vs proprietary
Trading involves risk. Past performance is not indicative of future results. Capital at risk. Full risk disclosure.